Comparison of behavioural effects of NocII or NocIII, two related pronociceptin-derived peptides
References (14)
- et al.
Eur. J. Pharmacol.
(1986) - et al.
Eur. J. Pharmacol.
(1996) - et al.
Nature
(1995) - et al.
Science
(1995) - et al.
FEBS Lett.
(1994) - et al.
- et al.
NeuroReport
(1995)
Cited by (7)
The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder
2023, NeuropharmacologyCitation Excerpt :Interestingly, although there are some sequence similarities between PDYN and PNOC (Houtani et al., 1996), the peptides derived from PNOC have minimal affinity for the other opioid receptors (Fig. 1; Zhang et al., 1997). The propeptide is processed to form 3 primary signaling peptides (Fig. 2): nociceptin/orphanin-FQ, nocistatin (Okuda-Ashitaka et al., 1998), whose target receptor(s) is unclear (Avenali et al., 2016; Kuspiel et al., 2021; Osmakov et al., 2019), and NocII/NocIII that produce behavioral effects when administered intracerebroventricularly (Florin et al., 1997, 1999) but whose effector(s) remains unknown. Although in vivo experiments reported that nociceptin and nocistatin might work in opposition (Okuda-Ashitaka et al., 1998), in whole cell electrophysiology in locus coeruleus (LC) neurons nocistatin application did not activate a conductance and it also did not block responses to nociceptin (Connor et al., 1999).
Pain peptides. Solution structure of orphanin FQ2
2000, FEBS LettersNocistatin: Milestone of one decade of research
2015, Current Pharmaceutical DesignOpioid system and Alzheimer's disease
2012, NeuroMolecular Medicine